Isogenix Limited
Registered name: ISOGENIX LIMITED
Part of Oxford Science Enterprises PLC groupIsogenix Limited does not publish its revenue or profit. Its accounts to 31 Dec 2025 show net assets of £885k and 4 employees.
Isogenix Limited did not publish its revenue or profit — small companies aren’t required to file a profit & loss account. Its accounts for the year to 31 Dec 2025 showed net assets of £885k and 4 employees. The company is classified under “research and experimental development on biotechnology” and is based in Oxford; we hold 3 years of its filed accounts.
- Status
- Active
- Location
- Oxford, South East
- Age
- 3 yrs · since 2022
- Type
- Private Limited Company
Part of a group. The filing indicates this company sits within a group structure, so its results may depend on intra-group trading and it may be hard to replicate independently.
Key figures
Revenue not disclosed
Isogenix Limited’s accounts for the year to 31 Dec 2025 contain a balance sheet but no profit & loss account, so its revenue and profit are not public. UK small and micro-entity companies are not required to publish a P&L — this is normal and says nothing about how the business is performing.
We never estimate revenue. Below you’ll find the balance-sheet figures that were filed — useful as indirect signals of momentum, but they are not revenue or profit.
- Employees
- 4
- Net assets
- £885k
Badges are automated estimates derived from the filed figures — not statements of fact about the company.
Financial history
| Year to | 31 Dec 2023 | 31 Dec 2024 | 31 Dec 2025 |
|---|---|---|---|
| Disclosure | No P&L | No P&L | No P&L |
| Profit & loss | |||
| Revenue (turnover) | — | — | — |
| Profit (best available) | — | — | — |
| Employees (average) | 1 | 4 | 4 |
| Ratios | |||
| Profit margin | — | — | — |
| Growth (year on year) | |||
| Headcount growth | — | ▲300% | 0% |
| Balance sheet — indirect signals, not revenue | |||
| Cash at bank | £3.1m | £2.2m | £752k |
| Net assets | £3.4m | £2.3m | £885k |
| Fixed assets | £146k | £88.9k | £35.1k |
| Current assets | £3.3m | £2.4m | £770k |
| Debtors | £209k | £251k | £17.8k |
| Deferred income | £6.5k | £21.4k | £21.4k |
| Source | FullAccounts · bulk data May 2024 | FullAccounts · bulk data Aug 2025 | FullAccounts · bulk data Aug 2026 |
Balance-sheet signals
Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.
- Net assets
- ▼62%
- Now £885k
- Cash at bank
- ▼65%
- Now £752k
- Headcount
- 0%
- Now 4
- Deferred income
- ▲0%
- Now £21.4k
- Fixed assets
- ▼60%
- Now £35.1k
Deferred income is reported together with accruals in this filing (“accruals and deferred income”), so it is an approximate signal only.
Group structure
Ownership chain
- Oxford Science Enterprises PLCultimate parent50–75%
- Isogenix Limitedthis company
Bands show the share of ownership each company holds in the one below it.
Sister companies (17)
- Oxford Science Enterprises Holdings II LimitedRev. £0 · Profit £243m
- Acionna Therapeutics LtdFigures not disclosed
- Alethio Therapeutics LimitedFigures not disclosed
- Animal Dynamics LimitedRev. — · Profit −£195k
- Circadian Therapeutics LimitedFigures not disclosed
- Credo Therapies LtdFigures not disclosed
- Dyna Therapeutics LimitedFigures not disclosed
- Kodiform Therapeutics LimitedFigures not disclosed
- Matchbio LimitedFigures not disclosed
- Nuanced Bio LtdFigures not disclosed
- Orfonyx Bio LtdFigures not disclosed
- Ose Labs LimitedFigures not disclosed
- Ose Manager LimitedFigures not disclosed
- Osi Midco LimitedFigures not disclosed
- Oxford Science Enterprises Holdings III LimitedFigures not disclosed
- Oxford Science Enterprises Holdings LimitedFigures not disclosed
- Thelior Bio LimitedFigures not disclosed
From the Persons with Significant Control register (corporate controllers only).
Similar profitable businesses
- Astex Therapeutics LimitedCambridge · Research and experimental development on biotechnology
- Revenue
- £404m
- Profit
- £283m
- Staff
- 183
- Amphista Therapeutics LimitedCambridge · Research and experimental development on biotechnology
- Revenue
- £33.9m
- Profit
- £19.8m
- Staff
- 56
- Charles River U.K. LimitedKent · Research and experimental development on biotechnology
- Revenue
- £22.2m
- Profit
- £18.8m
- Staff
- 129
- Qiagen Manchester LimitedManchester · Research and experimental development on biotechnology
- Revenue
- £53.7m
- Profit
- £11.8m
- Staff
- 239
- Alchemab Therapeutics LtdLondon · Research and experimental development on biotechnology
- Revenue
- £30m
- Profit
- £8.3m
- Staff
- 55
- Ligand UK Development LimitedLondon · Research and experimental development on biotechnology
- Revenue
- £8.7m
- Profit
- £6m
- Staff
- —
Sources
Latest figures from FullAccounts for the year to 31 Dec 2025, from the Companies House accounts bulk data published Aug 2026. Spotted an error? Request a correction.
Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.